Opus Genetics, Inc. (IRD) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
18/72
1.3 / 5 stars
All 72 Win/Lose results and 48 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseIRD / S&P -9.67% / 15.20% |
LoseIRD / S&P -36.09% / 15.00% |
LoseIRD / S&P -29.69% / 50.40% |
| 2026-Q11/3 |
WinIRD / S&P 126.37% / -4.33% |
LoseIRD / S&P -12.22% / 11.30% |
LoseIRD / S&P -36.67% / 27.70% |
| 2025-Q42/3 |
WinIRD / S&P 21.82% / 2.65% |
WinIRD / S&P 29.15% / 9.00% |
LoseIRD / S&P -61.86% / 13.40% |
| 2025-Q33/3 |
WinIRD / S&P 75.53% / 8.12% |
WinIRD / S&P 74.60% / 4.61% |
WinIRD / S&P 72.48% / 13.45% |
| 2025-Q21/3 |
LoseIRD / S&P -4.08% / 10.94% |
LoseIRD / S&P -6.25% / 4.83% |
WinIRD / S&P 249.09% / 10.63% |
| 2025-Q11/3 |
LoseIRD / S&P -17.65% / -4.27% |
LoseIRD / S&P -28.19% / 4.98% |
WinIRD / S&P 328.57% / 10.57% |
| 2024-Q41/3 |
LoseIRD / S&P -9.16% / 2.41% |
LoseIRD / S&P -42.30% / 5.25% |
WinIRD / S&P 347.92% / 6.15% |
| 2024-Q30/3 |
LoseIRD / S&P -14.38% / 5.89% |
LoseIRD / S&P -85.35% / 5.89% |
LoseIRD / S&P -176.76% / 6.11% |
| 2024-Q20/3 |
LoseIRD / S&P -23.88% / 4.28% |
LoseIRD / S&P -63.67% / 5.38% |
LoseIRD / S&P -157.89% / 5.12% |
| 2024-Q10/3 |
LoseIRD / S&P -33.22% / 10.56% |
LoseIRD / S&P -54.30% / 5.71% |
LoseIRD / S&P -152.13% / 5.59% |
| 2023-Q40/3 |
LoseIRD / S&P -10.15% / 11.69% |
LoseIRD / S&P -52.20% / 6.81% |
LoseIRD / S&P -155.17% / 7.78% |
| 2023-Q30/2 |
LoseIRD / S&P -22.81% / -3.27% |
No dataIRD / S&P / 7.52% |
LoseIRD / S&P -242.00% / -5.03% |
| 2023-Q22/3 |
WinIRD / S&P 15.73% / 8.74% |
WinIRD / S&P 9158.28% / 9.50% |
LoseIRD / S&P -192.23% / -8.57% |
| 2023-Q11/3 |
LoseIRD / S&P 6.23% / 7.50% |
WinIRD / S&P 6962.65% / 10.77% |
LoseIRD / S&P -172.31% / -15.69% |
| 2022-Q41/2 |
WinIRD / S&P 75.62% / 7.56% |
No dataIRD / S&P / 11.88% |
LoseIRD / S&P -119.25% / -17.99% |
| 2022-Q31/2 |
WinIRD / S&P 4.69% / -4.88% |
No dataIRD / S&P / 13.47% |
LoseIRD / S&P -87.52% / -1.41% |
| 2022-Q20/2 |
LoseIRD / S&P -40.74% / -16.10% |
No dataIRD / S&P / 13.71% |
LoseIRD / S&P -87.27% / 11.04% |
| 2022-Q10/2 |
LoseIRD / S&P -13.14% / -4.60% |
No dataIRD / S&P / 15.97% |
LoseIRD / S&P -83.75% / 42.23% |
| 2021-Q40/2 |
LoseIRD / S&P -27.57% / 11.03% |
No dataIRD / S&P / 15.00% |
LoseIRD / S&P -14.72% / 96.40% |
| 2021-Q30/1 |
LoseIRD / S&P -2.46% / 0.58% |
No dataIRD / S&P / 10.77% |
No dataIRD / S&P / 69.42% |
| 2021-Q20/1 |
LoseIRD / S&P -9.12% / 8.55% |
No dataIRD / S&P / 6.58% |
No dataIRD / S&P / 51.81% |
| 2021-Q10/1 |
LoseIRD / S&P -10.48% / 6.17% |
No dataIRD / S&P / -1.06% |
No dataIRD / S&P / 7.39% |
| 2020-Q40/1 |
LoseIRD / S&P -22.00% / 12.15% |
No dataIRD / S&P / -3.72% |
No dataIRD / S&P / -33.42% |
| 2020-Q30/1 |
LoseIRD / S&P -26.76% / 8.93% |
No dataIRD / S&P / -2.04% |
No dataIRD / S&P / -27.10% |
| 2020-Q21/1 |
WinIRD / S&P 57.78% / 20.54% |
No dataIRD / S&P / -0.46% |
No dataIRD / S&P / -27.11% |
| 2020-Q11/1 |
WinIRD / S&P -5.76% / -19.60% |
No dataIRD / S&P / 3.47% |
No dataIRD / S&P / -14.75% |
| 2019-Q40/1 |
LoseIRD / S&P -6.83% / 9.07% |
No dataIRD / S&P / 5.36% |
No dataIRD / S&P / 2.99% |
| 2019-Q30/1 |
LoseIRD / S&P -60.27% / 1.70% |
No dataIRD / S&P / 5.02% |
No dataIRD / S&P / 0.21% |
| 2019-Q20/1 |
LoseIRD / S&P -15.69% / 4.30% |
No dataIRD / S&P / 6.64% |
No dataIRD / S&P / 8.65% |
| 2019-Q10/1 |
LoseIRD / S&P -45.16% / 13.65% |
No dataIRD / S&P / 8.12% |
No dataIRD / S&P / 14.29% |
| 2018-Q40/1 |
LoseIRD / S&P -47.75% / -13.52% |
No dataIRD / S&P / 9.05% |
No dataIRD / S&P / 18.23% |
| 2018-Q31/1 |
WinIRD / S&P 26.24% / 7.71% |
No dataIRD / S&P / 10.21% |
No dataIRD / S&P / 19.06% |
| 2018-Q20/1 |
LoseIRD / S&P -6.62% / 3.43% |
No dataIRD / S&P / 9.03% |
No dataIRD / S&P / 14.46% |
| 2018-Q10/1 |
LoseIRD / S&P -25.25% / -0.76% |
No dataIRD / S&P / 7.68% |
No dataIRD / S&P / 12.46% |
| 2017-Q40/1 |
LoseIRD / S&P -16.53% / 6.64% |
No dataIRD / S&P / 7.03% |
No dataIRD / S&P / 13.82% |
| 2017-Q30/1 |
LoseIRD / S&P -15.38% / 4.48% |
No dataIRD / S&P / 5.68% |
No dataIRD / S&P / 17.57% |
| 2017-Q20/1 |
LoseIRD / S&P -43.92% / 3.09% |
No dataIRD / S&P / 4.83% |
No dataIRD / S&P / 17.74% |
| 2017-Q11/1 |
WinIRD / S&P 264.29% / 6.07% |
No dataIRD / S&P / 3.67% |
No dataIRD / S&P / 13.32% |
| 2016-Q40/1 |
LoseIRD / S&P -33.33% / 3.82% |
No dataIRD / S&P / 2.09% |
No dataIRD / S&P / 7.05% |
| 2016-Q30/1 |
LoseIRD / S&P -16.00% / 3.85% |
No dataIRD / S&P / 0.20% |
No dataIRD / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IRD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 215.57% | 20.78% |
| Annualized return | 215.57% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IRD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -14.25% | 83.14% |
| Annualized return | -3.03% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IRD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.79% | 319.30% |
| Annualized return | -29.10% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |